Tucatinib plus trastuzumab for HER2-positive rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign informed consent in writing
- Have rectal adenocarcinoma confirmed by biopsy (tissue confirmed as this cancer type)
- Have HER2-positive tumor confirmed by approved lab testing (IHC or special DNA testing like FISH/NGS)
- Have certain tumor markers: mismatch repair intact and RAS is wild-type
- Have no cancer that has spread to distant organs (no distant metastases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan and cetuximab, for people with colorectal cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of treatments given before surgery to shrink locally advanced HER2-positive rectal cancer. If you have this type of cancer, this approach might make surgery more successful and possibly allow you to keep your anus.
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Hear when a new Adenocarcinoma of the Rectum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.